Research Article
Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
Table 1
Patient and treatment characteristics.
| | Eyes (patients), n | 164 (134) | | Mean age (range), years | 75.9 (56–92) | | Women, n (%) | 75 (56.0) | | Angiographic classification, n (%) | | Occult with no classic | 95 (57.9) | | Predominantly classic | 37 (22.6) | | Minimally classic | 11 (6.7) | | Polypoidal choroidal vasculopathy | 14 (8.5) | | Retinal angiomatous proliferation | 7 (4.3) | | Eyes refractory to bevacizumab, n (%) | 101 (61.6) | | Eyes on treatment with ranibizumab, n (%) | 63 (38.4) | | Mean time on therapy ± SD, months | | Prior to switch | 28.5 ± 19.1 | | Aflibercept | 29.9 ± 9.0 |
|
|
